The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer
Age range from 18 to 80 years old, regardless of gender;
Pancreatic cancer was diagnosed by histopathology after radical surgery within 12 weeks before enrollment;
Did not receive neoadjuvant therapy before surgery and did not receive any adjuvant therapy after surgery;
ECOG score 0-3 points;
Known to be allergic to the components of Huaier granules or to avoid or use Huai er granules with caution (Huaier group);
Difficulties in taking oral medication due to active gastrointestinal bleeding, perforation, gastric paralysis, etc;
Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.
History of merging with other malignant tumors;
Xi'an Jiaotong University
Lead sponsor
LinkDoc Technology (Beijing) Co. Ltd.
Collaborator
Huazhong University of Science and Technology
Collaborator